Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO), has announced a major milestone in its sustainability roadmap with the development of a new 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, UK. This strategic investment underscores the company’s commitment to decarbonization and the integration of renewable energy into its global manufacturing network.
The ambitious solar installation will span approximately 16 acres of land and feature roughly 6,200 high-efficiency solar panels. Once the facility becomes operational—currently scheduled for the first quarter of 2027—it is expected to generate approximately 3,950 MWh of renewable electricity annually. This output will account for nearly 22% of the Morpeth site’s total yearly electricity demand. To put the scale of the project into perspective, the clean energy produced by the plant will be sufficient to power roughly 1,460 UK households each year.
The project is being facilitated through a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited, a specialized solar developer and independent power producer. This partnership model allows Piramal to secure a sustainable, cost-effective energy supply while simultaneously insulating the facility against energy market volatility, thereby enhancing operational resilience.
The environmental impact of the project is significant, with projections indicating that the site will avoid the emission of an estimated 20,000 tonnes of carbon dioxide equivalent (tCO₂e) over the next 25 years. This reduction is a pivotal component of Piramal’s long-term corporate decarbonization strategy, which seeks to minimize the environmental footprint of its pharmaceutical manufacturing processes.
Frank Bugg, Senior Vice President of UK & Europe Operations and Managing Director of Piramal Pharma Solutions, emphasized that the move is part of a broader corporate philosophy. “At Piramal Pharma Solutions, we integrate sustainability principles into every operation and decision across our global network,” Bugg said. “We are excited to advance our commitment to decarbonization and renewable energy with our partner Alight, bringing new value to our customers and shareholders worldwide.”
This renewable energy initiative arrives during a period of robust expansion and strategic consolidation for the parent company, Piramal Pharma Ltd. The company continues to widen its capabilities in the complex therapeutics space; notably, in August, the firm acquired an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based CDMO that specializes in high-growth areas such as vaccines and biologics.
By balancing heavy investment in cutting-edge pharmaceutical technologies with a parallel commitment to clean energy infrastructure, Piramal Pharma Solutions is positioning itself as a modern leader in the CDMO sector—proving that large-scale manufacturing and aggressive sustainability targets can go hand-in-hand. As the Morpeth site moves toward its 2027 commissioning, the company continues to demonstrate that green energy is no longer an optional add-on, but a core component of future-ready pharmaceutical supply chains.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
